AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval from the FDA for a lung cancer indication, seven months after ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer, TROP2-directed Datroway.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

Read about AstraZeneca PLC ADR (AZN:XNAS) stock and today's latest news and financial updates.

Review the current AstraZeneca PLC ADR (AZN:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if AZN is the best investment for you.